Information Provided By:
Fly News Breaks for November 21, 2016
NBIX, MYOV
Nov 21, 2016 | 07:16 EDT
Citi analyst Robyn Karnauskas started Myovant Sciences (MYOV) with a Buy rating and $17 price target. The analyst sees upside if the company meets enrollment timelines through 2017. Myovant's Relagolix is validated by Neurocrine's (NBIX) Elagolix, but may have greater convenience and efficacy, Karnauskas contends.
News For MYOV;NBIX From the Last 2 Days
NBIX
NBIX
NBIX
NBIX
NBIX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.